CHERRY HILL, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today that it has entered into a Joint Venture Agreement with Legacy Biotechnologies, Inc., a private company based in Tampa, Florida, to develop and market all natural remedies for symptoms of broad spectrum flu viruses.
Legacy Biotech has been heavily involved with research and development for the purpose of creating all natural remedies to help prevent and treat broad-spectrum flu-type symptoms resulting from influenza-like illnesses, including swine flu. Legacy Biotechnologies has finalized a two-step protocol that offers a unique method to help decrease the duration and severity of these symptoms that will be ready for the market within the next 60 days . As part of the Agreement, Nuvilex will share in the ongoing revenue stream derived from the sale of this product and Legacy Biotechnologies will obtain worldwide rights to certain Nuvilex intellectual property.
In addition, Legacy Biotechnologies will be working with one of the proprietary compounds previously developed by Knock-Out Technologies, Ltd., a wholly-owned subsidiary of Nuvilex. Legacy Biotechnologies will be conducting and funding specific clinical research to determine the general anti-viral capacity of the proprietary Knock-Out compound. The ultimate goal of joint venture is to allow Legacy Biotechnologies and Nuvilex to commercialize a full line of nutraceutical supplements with clinically validated anti-viral action.
"We are very excited to be joining with Legacy Biotechnology in this joint venture," stated Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "Although they work on differing modes of action, the natural remedies from Legacy Biotechnologies and the proprietary formula from Knock-Out Technologies complement each other synergistically. This joint venture allows both companies the chance to complete a comprehensive product line of all natural anti-viral treatments for broad-spectrum flu-type symptoms in a more thorough and expeditious manner."
About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Company Contact: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: firstname.lastname@example.org Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: email@example.com
|SOURCE Nuvilex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved